Every 8-K that Scilex Holding Company Warrant (SCLXW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SCLXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCLXW filings page.
Scilex Holding Company entered into a Promissory Note (Revolving Line of Credit) with Vivasor, Inc. effective August 8, 2026, establishing an uncommitted revolving credit facility with a maximum aggregate principal amount of up to $20,000,000. The facility has a stated maturity of 120 months from the effective date, with interest on borrowings at 5% per annum, accruing on each funded drawdown until repayment.
Vivasor may request multiple drawdowns before maturity, and repaid amounts may be reborrowed, but Scilex has no obligation to fund any request and may decide in its sole discretion. Any funded drawdown may be provided in cash, freely tradable Scilex securities, shares of Datavault AI, Inc. common stock currently held by Scilex or its subsidiaries, or a combination of these. All outstanding principal and accrued interest are due at maturity, and Vivasor may prepay at any time without penalty. The note becomes immediately due upon certain customary events of default. Dr. Henry Ji, Ph.D., Scilex’s Chief Executive Officer, President and Chairperson, also serves as Vivasor’s Chief Executive Officer, and the arrangement was approved by Scilex’s Board of Directors and Audit Committee.
Scilex Holding Company entered into a stock repurchase agreement with Vivasor Holding Company on July 18, 2026, under which Scilex agreed to sell 6,101,468 shares of Vivasor Series A-1 Preferred Stock and 355,919 shares of Vivasor Series A-2 Preferred Stock that Scilex had acquired in January 2026.
Vivasor will purchase these shares for an aggregate purchase price of $11,999,762.28, payable in cash by wire transfer, by assignment of Datavault AI, Inc. common stock held by a Vivasor subsidiary, or a combination of both. The price will be paid in five tranches between July 18, 2026 and June 30, 2027. The agreement includes customary representations, warranties, covenants and indemnification provisions. Scilex’s Chief Executive Officer, President and Chairperson, Dr. Henry Ji, Ph.D., also serves as Chief Executive Officer of Vivasor.
Scilex Holding Company entered into a binding term sheet with iHolding Group LLP for a proposed $100,000,000 equity investment in newly issued common shares. The parties expect a purchase price of $15.00 per share, which would represent approximately 6,666,667 shares if completed.
The proposal is subject to customary due diligence, negotiation and execution of definitive agreements, board and stockholder approvals, regulatory clearances and other closing conditions, and it may be modified or terminated. Scilex currently expects that, if structured as a private placement, the issuance would rely on exemptions under Section 4(a)(2) and Rule 506 of Regulation D. A press release describing the term sheet and intended use of proceeds for strategic growth, product development, acquisitions, working capital and other corporate purposes was furnished as an exhibit.
Scilex Holding Company has signed a binding term sheet to buy 837 Bitcoin from Datavault AI Inc. for $50 million. The assets are currently held in a Biconomy digital wallet, and the deal is structured as a proposed purchase rather than a completed acquisition.
Scilex plans an initial payment of $30 million, with the remaining $20 million in quarterly installments from the fourth quarter of 2026 through December 31, 2028. The company may pay in cash, common stock, publicly traded securities of its subsidiaries, or a mix, at its discretion. The transaction depends on negotiating a definitive agreement, securing approvals, and satisfying customary closing conditions, and may ultimately not be completed.
Scilex Holding Company reported voting results from its 2026 annual stockholder meeting. All Series A preferred shares, totaling 29,057,097, and 5,389,081 common shares were represented, based on 8,491,267 common shares outstanding as of April 28, 2026.
Stockholders elected Dorman Followwill as a Class I director, ratified BPM LLP as independent registered public accounting firm for the year ending December 31, 2026, and approved an amendment to the 2022 Equity Incentive Plan. The plan’s share reserve was increased by 1,300,000 shares to 2,765,789 shares, including the same total available for incentive stock options.
Scilex Holding Company is moving ahead with a previously declared special dividend of Dream Bowl Meme Coin I digital tokens to certain equity holders. Eligible record holders of common stock, specified warrants, Tranche B convertible notes, and Series A preferred stock as of April 30, 2026 will receive five Dream Bowl Tokens for each share of common stock held or underlying their securities.
The dividend is scheduled to begin paying on May 26, 2026, but the board may change the record or payment dates or revoke the dividend entirely. Holders must open a Datavault AI digital wallet and submit an Opt-In Agreement via the company’s dividend website to receive tokens. Scilex describes the Dream Bowl Token as a digital collectible with no equity, voting, or payment rights, initially valued at $0 per token as of May 8, 2026, and plans a future listing on the Biconomy cryptocurrency exchange.
Scilex Holding Company disclosed that indirect subsidiary ACEA Therapeutics agreed to sell 100% of ACEA Pharma to Phoenix Asia Holdings in a stock acquisition valued at $1,000,000,000.
ACEA Therapeutics will receive 100,000,000 newly issued Phoenix shares at $10.00 per share and is expected to own about 82% of Phoenix after closing. The transaction, unanimously approved by the boards, is expected to close by the end of the second quarter of 2026, subject to Hart-Scott-Rodino antitrust clearance, Nasdaq-related approvals and other customary conditions.
Scilex Holding Company entered into a binding term sheet with Datavault AI Inc. for a proposed cash contribution and revenue participation arrangement tied to Datavault’s planned Quantum-Ready Edge Network in about 100 U.S. cities.
Scilex expects to make an upfront cash contribution of $120,000,000, paid in multiple closings with the final closing no later than December 31, 2026. In return, Datavault would pay Scilex 30% of Network Revenues until payments total $250,000,000, then 15% until combined payments reach $1,200,000,000, and 5% of Network Revenues for the remaining lifetime of the GPUs purchased with the upfront funds. The arrangement remains subject to negotiation and execution of definitive agreements, satisfaction of customary closing conditions, and achievement of specified operational and financial milestones, and may ultimately not be completed.
Scilex Holding Company entered into a Warrant Agreement with Oramed Pharmaceuticals under which Oramed deferred an amortization payment on Scilex’s Tranche B senior secured convertible note that had been scheduled for October 1, 2025. In exchange, Scilex agreed to issue Oramed a new warrant to purchase 100,000 shares of common stock at an initial exercise price of $20.00 per share, called the February 2026 Warrant. The deferred amortization payment was ultimately made in November 2025, and the warrant is immediately exercisable and expires on December 13, 2029.
Scilex committed to file a registration statement to register the resale by Oramed of the shares issuable upon exercise, or to include them in another Form S-3. The warrant includes price-adjustment mechanisms, subject to a floor of $8.22 per share, a beneficial ownership cap initially at 4.99% (optionally adjustable up to 9.99% with notice), cashless exercise if no effective registration is available, and change-of-control protections allowing Oramed to require cash repurchase based on Black Scholes value.
Scilex Holding Company announced that its board of directors has revoked a previously declared stock dividend of 5,000,000 shares of Series 1 Mandatory Exchangeable Preferred Stock. This preferred stock had been authorized but no shares were ever issued.
In connection with the revocation, Scilex filed a Certificate of Elimination in Delaware, which became effective upon filing. This action eliminated the Series 1 designation and returned the 5,000,000 preferred shares to the company’s pool of undesignated preferred stock, effectively ending the special series that had been created for the contemplated dividend.
Scilex Holding Company entered into a financing and equity transaction with Quantum Scan Holdings, Inc. (Q Scan). Scilex loaned Q Scan $20 million under a convertible promissory note dated January 29, 2026, which fully converted that same day into 140,379,226 shares of Q Scan common stock.
Separately, Scilex agreed in a common stock purchase agreement to buy an additional 193,021,436 Q Scan shares for an aggregate price of approximately $27.5 million, with closing to occur within five business days after Q Scan delivers written notice. Scilex’s Chief Financial Officer, Stephen Ma, has served as Q Scan’s interim CFO since January 16, 2026 and, as of this report, has not received compensation from Q Scan in that role.
Scilex Holding Company disclosed changes in executive status and debtor-in-possession (DIP) financing arrangements. Dr. Ji is referenced in connection with a decision to resign as Chief Executive Officer and President to focus on Semnur, while the filing also states his compensation was not changed upon appointment as CEO and President and that he entered an indemnification agreement. The filing compares terms of a Junior DIP Loan (higher interest and fees: 14.0% vs 12.0%, maturity 5 vs 3 months, commitment/funding fees 2.5% vs 1.0%, exit fee 7.0% vs 2.0%). It describes a $100,000,000 Replacement DIP Facility provided by Oramed Pharmaceuticals, which refinanced the Senior DIP and included milestones and a lender credit-bid right for collateral (including equity interests). The Purchase Price for certain assets included a cash payment of $10,000,000 and assumption of approximately $12.25 million in legal fees; Sorrento retained 54,777 common shares in abeyance. A Pay-Off Letter would terminate the Junior DIP Loan Agreement and related security agreements upon Closing.